Article
KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Annals of surgical oncology - 1 May 2010
Italiano Antoine, Hostein Isabelle, Soubeyran Isabelle, Fabas Thibault, Benchimol Daniel, Evrard Serge, Gugenheim Jean, Becouarn Yves, Brunet René, Fonck Marianne, François Eric, Saint-Paul Marie-Christine, Pedeutour Florence
Abstract excerpt
BACKGROUND: KRAS and BRAF mutations in primary colorectal tumors (PT) are predictive of nonresponse to anti-epidermal growth factor receptor (EGFR) antibodies in patients with metastatic colorectal cancer (mCRC). The question of primary resistance to anti-EGFR treatment as a result of the presenc...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
